A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Recruiting

Phase 1

DCVC H1 HAA Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT05945485

Conditions

Influenza

Eligibility Criteria

Sex: All

Age: 18 - 49

Healthy Volunteers: Accepted

Interventions

DCVC H1 HA mRNA vaccine

Quadrivalent Recombinant Seasonal Influenza Vaccine

Sodium Chloride, 0.9%

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2024-11-04.